Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ICMT | O60725 | 15/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1819482 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTICMTLMNAGLA | |
| SCHEMBL20218608 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTICMTLMNAGLA | |
| SCHEMBL1819486 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTICMTLMNAGLA | |
| SCHEMBL21082139 | 0.77 | MAPT (0.54) | ALDH1A1MAPTICMT | |
| SCHEMBL13253069 | 0.77 | ALDH1A1 (0.63) | ALDH1A1MAPTICMT | |
| SCHEMBL20218613 | 0.75 | MAPT (0.77) | ALDH1A1MAPTICMT | |
| SCHEMBL21697764 | 0.75 | MAPT (0.77) | ALDH1A1MAPTICMT | |
| SCHEMBL20182261 | 0.74 | NPSR1 (0.63) | ALDH1A1MAPTLMNAGLACYP2C9 | |
| SCHEMBL20182273 | 0.74 | NPSR1 (0.63) | ALDH1A1MAPTLMNAGLACYP2C9 | |
| SCHEMBL18298108 | 0.73 | MAPT (0.77) | ALDH1A1MAPTICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330252-B1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10314802-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3075248-B1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | SIGNUM BIOSCIENCES INC (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3330252-A2 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | Signum Biosciences, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20170368011-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9744147-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744147-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744147-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170049841-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | SIGNUM DERMALOGIX, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170049841-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | SIGNUM DERMALOGIX, INC. | 2017-02-23 | — | — | US | disclosed |
| US-8372884-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. | 2013-02-12 | — | — | US | disclosed |
| US-8372884-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. | 2013-02-12 | — | — | US | disclosed |
| US-20110118265-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | SIGNUM DERMALOGIX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118265-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | SIGNUM DERMALOGIX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118265-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | SIGNUM DERMALOGIX, INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2011060330-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | SIGNUM BIOSCIENCES, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | SIGNUM BIOSCIENCES, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | SIGNUM BIOSCIENCES, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010056778-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049841-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | EPCAM, ELANE, CFTR | ALDH1A1 551/4885MAPT 4381/4885ICMT 2059/4885 |
| US-20110118265-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | EPCAM, ELANE, CFTR | ALDH1A1 551/4885MAPT 4381/4885ICMT 2059/4885 |
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | ALOX15B, ALOX15, ALOX5 | ALDH1A1 882/4885MAPT 4014/4885ICMT 267/4885 |
| US-10314802-B2 | Isoprenyl compounds and methods thereof | ALOX15B, ALOX15, ALOX5 | ALDH1A1 882/4885MAPT 4014/4885ICMT 267/4885 |
| US-20170368011-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | ALOX15B, ALOX15, ALOX5 | ALDH1A1 882/4885MAPT 4014/4885ICMT 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.